Arbutus Boosted by $2.25 Billion LNP Settlement and Hepatitis B Trial Progress
Claim 30% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Arbutus Biopharma ( (ABUS) ) is now available.
Arbutus Biopharma reported a solid financial position at year-end 2025, with $91.5 million in cash and securities, and highlighted a landmark $2.25 billion global settlement with Moderna over alleged infringement of its lipid nanoparticle delivery technology, from which Arbutus will receive a share through its license with Genevant. The company is also pursuing ongoing litigation with Pfizer/BioNTech over similar LNP patents, and is evaluating a potential return of capital to shareholders in the third quarter of 2026 after receiving its portion of the noncontingent payment.
On the clinical front, Arbutus announced that two additional patients in its Phase 2a trials of imdusiran for chronic hepatitis B achieved functional cure, bringing the total to 10, while maintaining viral suppression in previously cured patients who seroreverted. The company also recognized milestone revenue tied to Alnylam’s use of its LNP technology in a hepatocellular carcinoma candidate, underscoring the commercial relevance of its platform as it balances R&D progress with disciplined capital allocation and potential shareholder distributions.
The most recent analyst rating on (ABUS) stock is a Sell with a $4.00 price target. To see the full list of analyst forecasts on Arbutus Biopharma stock, see the ABUS Stock Forecast page.
Spark’s Take on ABUS Stock
According to Spark, TipRanks’ AI Analyst, ABUS is a Neutral.
The score is primarily constrained by weak financial performance (large losses, negative margins, declining revenue, and negative operating/free cash flow). Technicals are also soft with the price below key short- and mid-term moving averages and weak momentum indicators. Valuation is less supportive due to a negative P/E, and corporate events add uncertainty due to litigation and patent-related risks.
To see Spark’s full report on ABUS stock, click here.
More about Arbutus Biopharma
Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on developing treatments for infectious diseases, with a particular emphasis on chronic hepatitis B. The company also licenses its proprietary lipid nanoparticle delivery technology, which is used by third parties to deliver nucleic acid-based therapeutics, providing an additional source of revenue and strategic leverage in the biotech sector.
Average Trading Volume: 2,108,329
Technical Sentiment Signal: Buy
Current Market Cap: $815.5M
See more data about ABUS stock on TipRanks’ Stock Analysis page.
